All In Biotech

NDA 204630 · Provepharm Sas

Provayblue

Methylene Blue · Intravenous

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Dec 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 8, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

131

26 Phase 3, 11 recruiting

FAERS reports

1,578

1,470 serious, 257 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )]. WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS See full prescribing information for complete boxed warning. PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase...

What it is approved for

From the label in effect May 28, 2025.

PROVAYBLUE is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. PROVAYBLUE (methylene blue) is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.

Mechanism: Methylene blue is a water soluble thiazine dye that promotes a non-enyzmatic redox conversion of metHb to hemoglobin. In situ, methylene blue is first converted to leucomethylene blue (LMB) via NADPH reductase. It is the LMB molecule which then reduces the ferric iron of metHb to the ferrous state of normal hemoglobin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 8, 2024 Supplement 21 · Efficacy OrphanLabel
  • Apr 8, 2016 Original approval · Type 5 - New Formulation or New Manufacturer Accelerated approvalOrphanReviewSummary ReviewLetter
2 products under this application
  • PROVAYBLUE · METHYLENE BLUE 50MG/10ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • PROVAYBLUE · METHYLENE BLUE 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylene Blue" as an intervention, any sponsor and status, largest first.

All 131 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • serotonin syndrome469
  • drug interaction358
  • drug ineffective309
  • hypotension208
  • off label use185
  • toxicity to various agents141
  • overdose107
  • intentional overdose100
  • encephalopathy82
  • acute kidney injury76
  • toxic encephalopathy76
  • blood creatine phosphokinase increased72

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
20054
20067
200711
200813
200925
201038
201124
201223
201333
201419
201541
201672
201768
201877
201978
2020101
202196
2022146
2023180
2024162
2025248
2026103

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 672 on PubMed

Sponsor: Provepharm Sas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.